In summary, these results highlight that nanocarrier‐mediated FABP5 targeting significantly enhances RFA‐induced ICD and activates DC‐mediated immune responses, thereby amplifying anti‐tumor efficacy in HCC. Here, FABP5 is linked to neoplasm.